The 42nd Congress of the International Society of Oncology and Biomarkers “ONCOLOGY IN THE BIOMARKER ERA: Biology–Diagnostics–Therapy” ISOBM 2015
- 703 Downloads
KL-1. Honorary Lecture: The Ubiquitin Proteolytic System—From Basic Mechanisms thru Human Diseases and on to Drug Development
Aaron Ciechanover, M.D., D.Sc., Distinguished Research Professor, Cancer and Vascular Biology Research Center, Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
Between the 1950s and 1980s, most studies in biomedicine focused on the central dogma—the translation of the information coded by DNA to RNA and proteins. Protein degradation was a neglected area, considered to be a non-specific, dead-end process. While it was known that proteins do turn over, the high specificity of the process—where distinct proteins are degraded only at certain time points, or when they are not needed any more, or following denaturation/misfolding when their normal and active counterparts are spared—was not appreciated. The discovery of the lysosome by Christian de Duve did not significantly change this view, as it was clear that this...